The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Spain; AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; OncLive/MJH Life Sciences; Pfizer; PPD; Regeneron; Roche; Sanofi
 
Tudor-Eliade Ciuleanu
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Genzyme; Ipsen; Janssen; Lilly O.; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Genzyme; Ipsen; Janssen; Lilly O.; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
 
Michael Schenker
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; BeiGene; BIOVEN; Bristol-Myers Squibb; Clovis Oncology; Five Prime Therapeutics; Gilead Sciences; GlaxoSmithKline; Lilly; MSD; Mylan; Novartis; Pfizer/EMD Serono; Regeneron; Roche; Sanofi/Regeneron; Tesaro; Tesaro
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Manuel Cobo-Dols
No Relationships to Disclose
 
Stephanie Bordenave
No Relationships to Disclose
 
Oscar Juan-Vidal
No Relationships to Disclose
 
Juliana Janoski De Menezes
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex
 
Niels Reinmuth
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - Janssen
 
Eduardo Richardet
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novartis/Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer
 
Ying Cheng
No Relationships to Disclose
 
Hideaki Mizutani
No Relationships to Disclose
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; PharmaMar (Inst); Roche/Genentech; Specialised Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Xiaoqing Zhang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Nan Hu
No Relationships to Disclose
 
David Balli
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Vipul Baxi
Employment - Bristol-Myers Squibb
Leadership - Digital Pathology Association
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jaclyn Neely
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis